SCHEMBL100952

SCHEMBL100952

O=C(O)CCC(=O)c1ccc(Br)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.65
KMT2A Q03164 2/20 0.64
FFAR1 O14842 1/20 0.62
LMNA P02545 1/20 0.62
CYP1A2 P05177 1/20 0.62
RAB9A P51151 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
HIF1A Q16665 1/20 0.62
GSK3B P49841 2/20 0.59
ALDH1A1 P00352 1/20 0.59
GAA P10253 1/20 0.59
CYP2C19 P33261 1/20 0.59
USP5 P45974 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
HDAC1 Q13547 3/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC3 O15379 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7865681 0.94 SMN1; SMN2 (0.72) NR4A2KMT2AFFAR1LMNACYP1A2
SCHEMBL241664 0.91 GSK3B (0.70) KMT2ALMNASMN1; SMN2GSK3BALDH1A1
SCHEMBL10353454 0.89 NR4A2 (0.81) NR4A2KMT2AFFAR1LMNACYP1A2
SCHEMBL100781 0.88 HDAC1 (0.61) NR4A2KMT2AFFAR1LMNACYP1A2
SCHEMBL6138764 0.88 HDAC1 (0.66) NR4A2KMT2ALMNARAB9AGSK3B
SCHEMBL6931407 0.86 KMT2A (0.60) NR4A2KMT2AFFAR1LMNACYP1A2
SCHEMBL3381070 0.86 HDAC8 (0.69) LMNAGSK3BL3MBTL1HDAC1HDAC8
SCHEMBL7828372 0.86 HDAC8 (0.69) LMNAGSK3BL3MBTL1HDAC1HDAC8
SCHEMBL6925547 0.85 KMT2A (0.60) NR4A2KMT2ALMNAMEN1POLB
SCHEMBL10884944 0.82 SMN1; SMN2 (0.88) NR4A2KMT2AFFAR1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507651-A Recombinant transaminase and application thereof in preparation of chiral intermediate of nilapali 西南交通大学 2022-05-17 CN claimed
US-20260061083-A1 POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATGON (KR) 2026-03-05 US disclosed
US-12491271-B2 Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-12-09 US disclosed
EP-4545515-A1 BCL-2 INHIBITORS BeiGene Switzerland GmbH (CH) 2025-04-30 EP disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
CN-119192065-A Anticancer compounds 悉尼大学 2024-12-27 CN disclosed
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 US disclosed
WO-2024179529-A1 SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海海雁医药科技有限公司 2024-09-06 WO disclosed
US-12077536-B2 BCL-2 inhibitors BEIGENE, LTD. (KY) 2024-09-03 US disclosed
US-20240217953-A1 BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-07-04 US disclosed
US-4435329-A ANTIHYPERTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1984-03-06 US disclosed
EP-0010347-B1 NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION AMERICAN CYANAMID COMPANY (US) 1983-11-09 EP disclosed
US-4374249-A HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1983-02-15 US disclosed
EP-0001051-B1 DERIVATIVES OF BENZENESULFONAMIDE, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1981-02-11 EP disclosed
US-4235918-A SALIDIURETICS, TREATMENT OF HYPERTONIC CONDITIONS HOECHST AKTIENGESELLSCHAFT (DE) 1980-11-25 US disclosed
US-4226775-A HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1980-10-07 US disclosed
EP-0010347-A1 Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation AMERICAN CYANAMID COMPANY (US) 1980-04-30 EP disclosed
EP-0001051-A2 Derivatives of benzenesulfonamide, method for their preparation and pharmaceutical compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1979-03-21 EP disclosed
US-4082843-A 3-(3-(3-Substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines and their use as vasodilators and β-adrenergic blocking agents SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1978-04-04 US disclosed
US-4058529-A Polycyclic amino derivatives of pyrrolidone and piperidone CIBA-GEIGY CORPORATION (US) 1977-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077536-B2 BCL-2 inhibitors BCL2, BCL2L1, BCL2L2 NR4A2 1375/4885KMT2A 2464/4885FFAR1 2234/4885
US-20260061083-A1 POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR TSPO, FABP7, SLC46A1 NR4A2 3471/4885KMT2A 4473/4885FFAR1 251/4885
US-12491271-B2 Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor TSPO, FABP7, SLC46A1 NR4A2 1966/4885KMT2A 4255/4885FFAR1 120/4885
US-20240376104-A1 Bcl-2 Inhibitors BCL2, BCL2L1, BCL2L2 NR4A2 1375/4885KMT2A 2464/4885FFAR1 2234/4885
US-20240217953-A1 BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID COMPOUNDS C9, CFB, C5 NR4A2 1171/4885KMT2A 3995/4885FFAR1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.